Smart biopsy devices market seen growing to $4.32 billion by 2030

The smart biopsy devices market is projected to rise from $3.01 billion in 2025 to $3.23 billion in 2026, with the forecast pointing to $4.32 billion by 2030. Growth is being driven by rising cancer cases, broader use of minimally invasive diagnostics and more AI-linked, robotic-assisted procedures.

Why it matters: - Smart biopsy devices are becoming more important as health systems look for faster, more precise tissue sampling. - The market outlook points to stronger demand for tools that can improve cancer diagnosis, treatment planning and patient safety. - The forecasted 7.6% CAGR through 2030 signals sustained investment in precision oncology and smart surgical technology.

What happened: - The Business Research Company released its Smart Biopsy Devices Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The market is projected to grow from $3.01 billion in 2025 to $3.23 billion in 2026. - The report forecasts the market will reach $4.32 billion by 2030. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - Download a free sample of the report. - View the full market report.

The details: - Smart biopsy devices are advanced tools designed to improve the precision and efficiency of tissue sampling. - The devices combine image guidance, real-time feedback and robotic assistance. - Primary uses include cancer diagnosis and therapeutic drug delivery. - Reported growth drivers include rising cancer rates, more use of minimally invasive diagnostic methods, expansion of advanced imaging infrastructure, wider adoption of core needle biopsy techniques and better clinician expertise in image-guided procedures. - Forecast drivers include demand for precision oncology diagnostics, investment in smart surgical technologies, growth in robotic-assisted intervention platforms, emphasis on early disease detection and AI-based diagnostic support systems. - Key trends include greater use of image-guided biopsy systems, robotic-assisted biopsy procedures, real-time tissue feedback technologies, minimally invasive diagnostic techniques and a stronger focus on diagnostic accuracy and patient safety. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - Rising cancer incidence is the clearest demand driver because it increases the need for targeted tissue sampling and earlier detection. - The move toward robotic and AI-enabled biopsy tools suggests the market is shifting from standard sampling toward more guided, data-driven procedures. - North America’s lead and Asia-Pacific’s faster growth indicate a split between current infrastructure strength and future expansion potential. - The World Health Organization projected more than 35 million new cancer cases by 2050, up 77% from an estimated 20 million cases in 2022, underscoring the scale of the diagnostic need.

What's next: - The market is expected to keep expanding as hospitals and diagnostic providers adopt more precise and less invasive biopsy technologies. - Growth is likely to track continued investment in imaging systems, robotic platforms and AI-supported clinical workflows. - Asia-Pacific’s share of growth could rise as healthcare access and medical technology investment expand.

The bottom line: - Smart biopsy devices are moving from niche clinical tools to a broader growth market tied to cancer detection, precision medicine and automated diagnostics.